Clinical trial
A Randomized, Controlled, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Breast Cancer and Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Advanced Breast With Liver Metastases
NCT03500380 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Breast Cancer and Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Advanced Breast With Liver Metastases
- Lead sponsor
- RemeGen Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- April 24, 2018
- Completion date
- December 31, 2024
- Enrollment
- 301 (estimated)
- Sites
- 67
Conditions
As the registry lists them; a condition with its own page is linked.
breast diseases, breast neoplasms, capecitabine, her2 positive breast carcinoma, her2-positive advanced breast with liver metastases, her2-positive breast cancer